94 result(s)
GSK Medical
This online medical resource for scientific and clinical information is intended to share the latest development in clinical research on GSK Products
Respiratory Syncytial Virus
Respiratory syncytial virus (RSV) is an important cause of respiratory illness in all ages, including vulnerable adults. Learn about RSV and the associated disease in adults.1
Educational Webinars (*Stand Alone*)
View disease educational resources from GSK oncology
Oncology
This area of the website is intended for HCPs specializing in Oncology. GSK does not support or endorse any use of its products that is not consistent with the approved prescribing information in the official product monograph
GSK at Conferences
GSK Oncology will have a presence at these meetings. Please visit us at our scientific booth or view our scientific information
Pipeline
Our unique R&D approach of Science x Technology x Culture is helping to fight cancer on multiple groundbreaking fronts – focusing on maximizing survival through the discovery and development of novel oncology medicines that may have life-changing potential.
Congress Presentations
View congress posters and presentations from GSK oncology to learn about the latest developments in clinical research on GSK oncology products.
Pipeline
Our unique R&D approach of Science x Technology x Culture is helping to fight cancer on multiple groundbreaking fronts – focusing on maximizing survival through the discovery and development of novel oncology medicines that may have life-changing potential.
Resource Links
View resources from medical organizations, patient advocacy organizations as well as global and local guidelines.
Patient Empowerment Alliance
Learn about the Patient Empowerment Alliance (P.E.A.), an innovative part of the GSK Supported Studies Program.
Disease Information
View videos from GSK oncology on mechanism of disease as well as other disease education resources.
Educational Webinars
View disease educational resources from GSK oncology
Mechanism of Disease
View material from GSK oncology on proposed, mechanism of disease of various cancers.
GSK Medical - Please request a contact confirmation Form
Contact us form for UK healthcare professionals to contact GSK
Risk Factors and Clinical Burden of RSV in Older Adults
While RSV-related infections usually present as mild cold-like symptoms in adults, some cases may lead to more serious respiratory complications, hospitalization and death, particularly in older adults and those with underlying conditions1
A New Study Highlights the Need for the Meningitis B Vaccine for Children in New Zealand
Time to complete: X minutes All Credits Available Physicians - Maximum of 1.00 AMA PRA Category 1 Credit(s)™ ABIM Diplomates - Maximum of 1.00 ABIM MOC points
Respiratory Syncytial Virus in Adults: Microlessons in Burden, Prevention, and Vaccination
Time to complete: X minutes All Credits Available Physicians - Maximum of 0.50 AMA PRA Category 1 Credit(s)
GSK Medical - Please request a contact confirmation Form
Contact us form for UK healthcare professionals to contact GSK
Patient management
Treatment options for herpes zoster are suboptimal and may have limited efficacy and poor tolerability in some patients. Therefore, improvements are needed in the prevention and management of herpes zoster.1,2
Real-world evidence for the recombinant zoster vaccine (RZV)
Since the first approval of the recombinant zoster vaccine (RZV) against herpes zoster (HZ) in 2017, evidence for its use in real-world settings has been generated through real-world studies.
Co-administration of the recombinant zoster vaccine (RZV) with other adult vaccines
Throughout life, vaccines are recommended to protect individuals from vaccine-preventable diseases.
Burden of disease and complications
Burden of disease and complications
Epidemiology and risk factors
Herpes zoster is caused by the reactivation of the varicella zoster virus.
Prevention through vaccination: Immunocompromised patients
Efficacy, immunogenicity, and safety of the adjuvanted recombinant zoster vaccine (RZV) in immunocompromised subjects
Herpes Zoster
Herpes zoster, also known as shingles, is a painful condition caused by reactivation of the varicella zoster virus, the same virus that causes chickenpox.1-4
Disease Information
View disease information content from GSK Vaccines
Vaccines
GSK Vaccines Medical
GSK Medical | Pipeline
Strengthening our R&D pipeline through a focus on science related to the immune system, the use of the human genetics, and advanced technologies
Educational Webinars
View videos from GSK oncology on mechanism of disease as well as other disease education resources.
Prevention through vaccination: The ZOE programme - RZV pivotal and extension studies in individuals over 50 years of age
The efficacy of the Recombinant Zoster Vaccine (RZV) was evaluated in two Phase 3 clinical trials, Zoster Efficacy Study in Adults 50 Years of Age or Older (ZOE-50, NCT01165177) and Zoster Efficacy Study in Adults 70 Years of Age or Older (ZOE-70, NCT01165229).1,2 The Zoster-049 study (NCT02723773) is an ongoing long-term follow-up (LTFU) study of the ZOE-50 and ZOE-70 studies.3,4
Load more
No results. Why not try:
- Checking the spelling of the search term
- A different search term
- Resetting or revising the filter settings